Resultado da Busca
Há 1 dia · e13735 Background: Rectal cancer (RC) has seen a decreasing incidence and mortality due to national screening guidelines, innovative therapies and new technology. In recent years, however, we have noted shifts in its demographics pertaining to variation in stage at diagnosis and mortality rates amongst various ethnic groups. Minority populations, namely Hispanic (H) and Black (B) patients (pts ...
Há 5 dias · Background: Early-onset colorectal cancer (EO-CRC) is defined as colorectal cancer diagnosed before the age of 50 years, and its incidence has been increasing over the last decade, now accounting for 10% of all new CRC diagnoses. Average-onset colorectal cancer (AO-CRC) has shown a steady decline in its incidence and related mortality over the past 20 years. The disparities in outcomes and ...
Há 5 dias · British Journal of Cancer - Death receptors 4/5 mediate tumour sensitivitNot applicably to natural killer cell-mediated cytotoxicity in mismatch repair deficient colorectal cancer Skip to main content
Há 5 dias · Detection and diagnosis of colon polyps are key to preventing colorectal cancer. ... Global burden of colorectal cancer in 2020 and 2040: incidence and mortality ... Sci. Rep. 14, 2032 ...
Há 5 dias · The incidence of colorectal cancer among younger people in the U.S. has been steadily rising over the past two decades, with the most significant increases observed in the youngest age groups. A study recently presented at Digestive Disease Week (DDW) 2024 found that from 1999 to 2020, the rate of colorectal cancers increased by 500% among ...
Há 4 dias · Treatment of advanced colorectal cancer (CRC) has seen a rapid succession of significant advances, from the introduction of novel conventional cytotoxics (such as oxaliplatin and irinotecan) to, more recently, the antiangiogenic agent bevacizumab and epidermal growth factor-receptor antibodies, such as cetuximab and panitumumab.
Há 3 dias · Tabernero J, Cohn AL, Obermannova R, et al. RAISE: A randomized, double-blind, multicenter phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab (RAM) or placebo (PBO) in patients (pts) with metastatic colorectal carcinoma (CRC) progressive during or following first-line combination therapy with bevacizumab ...
